SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Revance Therapeutics, Inc. – ‘10-K’ for 12/31/14 – ‘EX-32.2’

On:  Wednesday, 3/4/15, at 5:08pm ET   ·   For:  12/31/14   ·   Accession #:  1628280-15-1461   ·   File #:  1-36297

Previous ‘10-K’:  ‘10-K’ on 3/28/14 for 12/31/13   ·   Next:  ‘10-K’ on 3/4/16 for 12/31/15   ·   Latest:  ‘10-K’ on 2/28/24 for 12/31/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/04/15  Revance Therapeutics, Inc.        10-K       12/31/14  101:15M                                    Workiva Inc Wde… FA01/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.45M 
 2: EX-10.25    Material Contract                                   HTML     35K 
 3: EX-10.40    Material Contract                                   HTML     63K 
 4: EX-10.42    Material Contract                                   HTML    206K 
 5: EX-23.1     Consent of Experts or Counsel                       HTML     29K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     35K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     35K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     32K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     32K 
70: R1          Document and Entity Information                     HTML     59K 
56: R2          Consolidated Balance Sheets                         HTML    140K 
68: R3          Consolidated Balance Sheets (Parenthetical)         HTML     63K 
73: R4          Consolidated Statement of Operations and            HTML    109K 
                Comprehensive Loss                                               
92: R5          Consolidated Statements of Changes in Convertible   HTML    256K 
                Preferred Stock and of Stockholders’ Equity                      
                (Deficit)                                                        
59: R6          Consolidated Statements of Changes in Convertible   HTML     41K 
                Preferred Stock and of Stockholders’ Equity                      
                (Deficit) (Parenthetical)                                        
67: R7          Consolidated Statements of Cash Flows               HTML    234K 
51: R8          The Company and Basis of Presentation               HTML     44K 
41: R9          Summary of Significant Accounting Policies          HTML     83K 
93: R10         License Agreements                                  HTML     37K 
75: R11         Medicis Settlement                                  HTML     43K 
74: R12         Fair Value Measurements                             HTML    123K 
80: R13         Balance Sheet Components                            HTML     82K 
81: R14         Notes Payable                                       HTML     60K 
78: R15         Convertible Notes, Warrants, and Related            HTML     61K 
                Derivatives                                                      
82: R16         Interest Expense                                    HTML     62K 
69: R17         Commitments and Contingencies                       HTML     47K 
71: R18         Common Stock                                        HTML     51K 
77: R19         Convertible Preferred Stock                         HTML     62K 
101: R20         Warrants                                            HTML     64K  
88: R21         Stock Option Plan                                   HTML    232K 
63: R22         Net Income (Loss) per Share Attributable to Common  HTML     80K 
                Stockholders                                                     
76: R23         Income Taxes                                        HTML     93K 
65: R24         Defined Contribution Plan                           HTML     34K 
32: R25         Subsequent Events                                   HTML     37K 
89: R26         Quarterly Results of Operations (Unaudited)         HTML     86K 
97: R27         Summary of Significant Accounting Policies          HTML    147K 
                (Policies)                                                       
46: R28         Fair Value Measurements (Tables)                    HTML    117K 
45: R29         Balance Sheet Components (Tables)                   HTML     85K 
49: R30         Notes Payable (Tables)                              HTML     42K 
50: R31         Convertible Notes, Warrants, and Related            HTML     41K 
                Derivatives (Tables)                                             
52: R32         Interest Expense (Tables)                           HTML     60K 
24: R33         Commitments and Contingencies (Tables)              HTML     37K 
86: R34         Common Stock (Tables)                               HTML     48K 
61: R35         Convertible Preferred Stock (Tables)                HTML     52K 
64: R36         Warrants (Tables)                                   HTML     52K 
36: R37         Stock Option Plan (Tables)                          HTML    210K 
100: R38         Net Income (Loss) per Share Attributable to Common  HTML     81K  
                Stockholders (Tables)                                            
16: R39         Income Taxes (Tables)                               HTML     83K 
53: R40         Quarterly Results of Operations (Unaudited)         HTML     85K 
                (Tables)                                                         
91: R41         The Company and Basis of Presentation - Additional  HTML     90K 
                Information (Detail)                                             
34: R42         Summary of Significant Accounting Policies          HTML     71K 
                (Details)                                                        
44: R43         License Agreements (Details)                        HTML     52K 
48: R44         Medicis Settlement - Additional Information         HTML     79K 
                (Detail)                                                         
57: R45         Fair Value Measurements - Schedule of Fair Value    HTML     89K 
                of Financial Instruments (Detail)                                
23: R46         Fair Value Measurements - Summary of Changes in     HTML     95K 
                Fair Value of Financial Instruments (Detail)                     
40: R47         Fair Value Measurements (Narrative) (Details)       HTML     31K 
18: R48         Balance Sheet Components - Additional Information   HTML     38K 
                (Detail)                                                         
90: R49         Balance Sheet Components - Schedule of Property     HTML     55K 
                and Equipment, Net (Detail)                                      
33: R50         Balance Sheet Components - Schedule of Prepaid      HTML     42K 
                Expenses and Other Current Assets (Detail)                       
87: R51         Balance Sheet Components - Schedule of Accruals     HTML     57K 
                and Other Current Liabilities (Detail)                           
37: R52         Balance Sheet Components - Schedule of Other        HTML     40K 
                Non-Current Assets (Detail)                                      
54: R53         Notes Payable - Hercules Notes Payable (Detail)     HTML     97K 
17: R54         Notes Payable - Essex Capital Notes (Detail)        HTML    111K 
21: R55         Notes Payable - Summary of Aggregate Total Future   HTML     37K 
                Minimum Lease Payments under the Financing                       
                Obligation (Detail)                                              
47: R56         Notes Payable - Summary of Future Principal         HTML     44K 
                Payments under the Notes Payable (Detail)                        
27: R57         Convertible Notes, Warrants, and Related            HTML    154K 
                Derivatives - Additional Information (Detail)                    
94: R58         Convertible Notes, Warrants, and Related            HTML     46K 
                Derivatives - Fair Value Assumptions Using "Monte                
                Carle" Simulation (Details)                                      
60: R59         Interest Expense - Summary of Interest Expense by   HTML     56K 
                Cash and Non-Cash Components (Detail)                            
79: R60         Commitments and Contingencies - Additional          HTML     44K 
                Information (Detail)                                             
39: R61         Commitments and Contingencies - Schedule of Future  HTML     48K 
                Minimum Lease Payments under Non-Cancelable                      
                Operating Leases (Detail)                                        
42: R62         Common Stock - Additional Information (Detail)      HTML     61K 
85: R63         Convertible Preferred Stock - Additional            HTML    137K 
                Information (Detail)                                             
83: R64         Convertible Preferred Stock - Outstanding           HTML     80K 
                (Details)                                                        
62: R65         Warrants - Additional Information (Detail)          HTML    151K 
84: R66         Warrants - Schedule of Warrants (Details)           HTML     55K 
38: R67         Warrants - Assumptions Using Black-Scholes Model    HTML     39K 
                (Details)                                                        
66: R68         Stock Option Plan - Additional Information          HTML    140K 
                (Detail)                                                         
96: R69         Stock Option Plan - Summary of Stock Option and     HTML    175K 
                Restricted Stock Award Activity (Details)                        
20: R70         Stock Option Plan - Stock Options Outstanding and   HTML     89K 
                Exercisable (Details)                                            
31: R71         Stock Option Plan - Summary of Restricted Stock     HTML     64K 
                Award Activity (Details)                                         
55: R72         Stock Option Plan - Fair Value Assumptions          HTML     59K 
                (Details)                                                        
26: R73         Stock Option Plan - Schedule of Stock-based         HTML     41K 
                Compensation Expense (Details)                                   
99: R74         Net Income (Loss) per Share Attributable to Common  HTML    104K 
                Stockholders - Schedule of Computation of Basic                  
                and Diluted Net Income (Loss) Per Share                          
                Attributable to Common Stockholders (Detail)                     
35: R75         Net Income (Loss) per Share Attributable to Common  HTML     50K 
                Stockholders - Summary of Common Stock Equivalents               
                Excluded from Computation of Diluted Net Income                  
                (Loss) Per Share (Detail)                                        
28: R76         Income Taxes - Additional Information (Detail)      HTML     61K 
30: R77         Income Taxes - Deferred Tax Assets and Liabilities  HTML     61K 
                (Details)                                                        
22: R78         Income Taxes - Effective Tax Rate Reconciliation    HTML     58K 
                (Details)                                                        
25: R79         Income Taxes - Unrecognized Tax Benefits (Details)  HTML     40K 
72: R80         Defined Contribution Plan - Additional Information  HTML     31K 
                (Details)                                                        
29: R81         Subsequent Events - Additional Information          HTML     82K 
                (Details)                                                        
95: R82         Quarterly Results of Operations (Unaudited) -       HTML     67K 
                Additional Information (Details)                                 
98: XML         IDEA XML File -- Filing Summary                      XML    166K 
19: EXCEL       IDEA Workbook of Financial Reports                  XLSX    270K 
43: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   2.07M 
10: EX-101.INS  XBRL Instance -- rvnc-20141231                       XML   3.11M 
12: EX-101.CAL  XBRL Calculations -- rvnc-20141231_cal               XML    254K 
13: EX-101.DEF  XBRL Definitions -- rvnc-20141231_def                XML    895K 
14: EX-101.LAB  XBRL Labels -- rvnc-20141231_lab                     XML   2.31M 
15: EX-101.PRE  XBRL Presentations -- rvnc-20141231_pre              XML   1.37M 
11: EX-101.SCH  XBRL Schema -- rvnc-20141231                         XSD    250K 
58: ZIP         XBRL Zipped Folder -- 0001628280-15-001461-xbrl      Zip    322K 


‘EX-32.2’   —   Certification — §906 – SOA’02


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  RVNC 12.31.2014 10K EX32.2  



CERTIFICATION
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Lauren P. Silvernail, Chief Financial Officer of Revance Therapeutics, Inc. (the “Company”), hereby certifies that, to the best of her knowledge:

1.
The Company’s Annual Report on Form 10-K for the period ended December 31, 2014 (the “Annual Report”), to which this Certification is attached as Exhibit 32.2,fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and

2.
The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

In Witness Whereof, the undersigned has set her hand hereto as of the 4th day of March, 2015.
 
 
 
Chief Financial Officer
 

“This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Revance Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.”





Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/4/15S-3
For Period end:12/31/14ARS
 List all Filings 
Top
Filing Submission 0001628280-15-001461   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Apr. 18, 6:13:16.1pm ET